Most Closely HLA-Matched Allogeneic LMP1/2-Specific Cytotoxic T Lymphocytes for Treatment of Patients With Relapsed EBV-Associated Diseases

Trial Profile

Most Closely HLA-Matched Allogeneic LMP1/2-Specific Cytotoxic T Lymphocytes for Treatment of Patients With Relapsed EBV-Associated Diseases

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Feb 2017

At a glance

  • Drugs Baltaleucel-T (Primary)
  • Indications Epstein-Barr virus infections; Hodgkin's disease; Leiomyosarcoma; Lymphoproliferative disorders; Nasopharyngeal cancer; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Acronyms MALTED
  • Most Recent Events

    • 03 Feb 2016 Planned End Date changed from 1 Feb 2021 to 1 Feb 2020 as per ClinicalTrials.gov record.
    • 03 Feb 2016 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
    • 09 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top